title: Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells.
abstract: Tautomycetin (TMC), originally isolated from Streptomyces griseochromogenes, has been suggested as a potential drug retaining specificity toward colorectal cancer. However, we found that TMC exhibited inhibitory effects on cell proliferation of many cancer cell lines including adriamycin-resistant human breast adenocarcinoma. We investigated its anti-tumor activity and mechanisms in human breast cancer cells for the first time. In this study, we showed that TMC effectively inhibited breast cancer cell proliferation, migration, and invasion. TMC also induced apoptosis in MCF-7 cells. This apoptotic response was in part mediated by Bcl-2 cleavage, leading to the release of cytochrome c, which facilitates binding of Apaf-1 to caspase-9 in its presence and subsequent activation of caspase-7 in apoptosis induction signaling pathways. Furthermore, we identified that TMC induced apoptosis by suppressing Akt signaling pathway activation, which is independent of protein phosphatase PP1 inhibition. The levels of downstream targets of Akt, including phospho-forkhead transcription factor and Bad, were also reduced after TMC treatment. Overall, our results indicate that TMC could be used as a potential drug candidate for breast cancer therapy. More importantly, our study provides new mechanisms for the anticancer effects of TMC.
authors.affiliation: Research Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, China.
authors.forename: Mingshan
authors.initials: M
authors.lastname: Niu
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Xuejiao
authors.initials: X
authors.lastname: Liu
authors.forename: Li
authors.initials: L
authors.lastname: Tang
authors.forename: Rongguo
authors.initials: R
authors.lastname: Qiu
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D053477:Apoptotic Protease-Activating Factor 1 / Q000378:metabolism; D001943:Breast Neoplasms / Q000473:pathology*; D053179:Caspase 7 / Q000378:metabolism; D053453:Caspase 9 / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D045304:Cytochromes c / Q000378:metabolism; D005260:Female; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D008055:Lipids / Q000494:pharmacology*; D061986:MCF-7 Cells; D051058:Oncogene Protein v-akt / Q000502:physiology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology*; D014407:Tumor Cells, Cultured
chemical_list: C506592:APAF1 protein, human; D000970:Antineoplastic Agents; D053477:Apoptotic Protease-Activating Factor 1; D005663:Furans; D008055:Lipids; D019253:Proto-Oncogene Proteins c-bcl-2; D017476:Receptors, Neuropeptide Y; C058744:tautomycetin; C109491:neuropeptide Y4 receptor; D045304:Cytochromes c; D051058:Oncogene Protein v-akt; D053179:Caspase 7; D053453:Caspase 9